caffeine has been researched along with bromocriptine in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Calne, DB; Kartzinel, R; Shoulson, I | 1 |
| Andén, NE; Casas, M; Ferré, S; Grabowska-Andén, M; Herrera-Marschitz, M; Ungerstedt, U | 1 |
| Asami, T; Ida, I; Kuribara, H; Machiyama, Y; Tadokoro, S | 1 |
| Berchou, RC; Kareti, D; LeWitt, PA; Nelson, MV | 1 |
| Barbanoj, M; Casas, M; Jané, F; Kulisevsky, J; Prat, G; Robledo, P | 1 |
| Barbanoj, M; Casas, M; Jané, F; Prat, G; Robledo, P; Rubio, A | 1 |
| Cauli, O; Fenu, S; Morelli, M | 1 |
1 review(s) available for caffeine and bromocriptine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for caffeine and bromocriptine
| Article | Year |
|---|---|
Studies with bromocriptine: III. Concomitant administration of caffeine to patients with idiopathic parkinsonism.
Topics: Bromocriptine; Caffeine; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Ergolines; Female; Humans; Male; Middle Aged; Parkinson Disease; Phosphodiesterase Inhibitors | 1976 |
11 other study(ies) available for caffeine and bromocriptine
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
Postsynaptic dopamine/adenosine interaction: II. Postsynaptic dopamine agonism and adenosine antagonism of methylxanthines in short-term reserpinized mice.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Animals; Bromocriptine; Caffeine; Dopamine; Male; Mice; Motor Activity; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Reserpine; Sulpiride; Synapses; Theophylline; Xanthines | 1991 |
[Characteristics of antagonism between ceruletide and various central-acting drugs: investigation by means of ambulatory activity in mice].
Topics: Animals; Bromocriptine; Caffeine; Ceruletide; Cocaine; Dose-Response Relationship, Drug; Drug Tolerance; Ephedrine; Haloperidol; Male; Methamphetamine; Methylphenidate; Mice; Morphine; Motor Activity; Scopolamine | 1990 |
Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine.
Topics: Adult; Bromocriptine; Caffeine; Drug Interactions; Erythromycin; Humans; Male; Middle Aged | 1990 |
Repeated co-administration of caffeine and bromocriptine prevents tolerance to the effects of caffeine in the turning behavior animal model.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Bromocriptine; Caffeine; Central Nervous System Stimulants; Dopamine Agonists; Drug Therapy, Combination; Drug Tolerance; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinson Disease; Rats | 1999 |
Effects of sub-chronic combined treatment with pergolide and caffeine on contralateral rotational behavior in unilateral 6-hydroxydopamine-denervated rats.
Topics: Animals; Bromocriptine; Caffeine; Denervation; Drug Administration Schedule; Drug Combinations; Drug Tolerance; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pergolide; Rats; Rats, Sprague-Dawley; Rotation | 2000 |
Cross-sensitization between the motor activating effects of bromocriptine and caffeine: role of adenosine A(2A) receptors.
Topics: Animals; Bromocriptine; Caffeine; Central Nervous System Stimulants; Dopamine Agonists; Dose-Response Relationship, Drug; Male; Motor Activity; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Purinergic P1; Stereotyped Behavior; Stimulation, Chemical; Triazoles | 2000 |